Avacta Group PLC · LSE:AVCT
Avacta — FY2013 Earnings Presentation
19 slides from Avacta's earnings presentation, Nov 16, 2013
Slide 1: Avacta Group plc: Preliminary Results for the Period ending 31st July 2013
Avacta Group plc ! Innovation for global health! Preliminary Results for the Period ending 31st July 2013! © Avacta Group plc!
Slide 2: Overview
Overview Avacta is a global provider of proprietary diagnostic tools, consumables and reagents to the drug development, diagnostics, R&D and healthcare sectors.! ! L I F E S C I E N C E S! Analytical technology for Veterinary diagnostics Reagents and tools for life biotech – market leading products
Slide 3: Revenue, Funds Raised, Market Capitalisation, Shareholders
3! Revenue! Funds Raised! £17.2m! £1.6m! £1.6m! £1.7m! £12.5m! £0.9m! £0.9m! £1m! £7.4m! £0.5m! £0.4m! £6m! H1! H2! H1! H2! H1! H2! H1! H2! 2010 ! 2011! 2012! 2013! 2006-9 ! 2010! 2012! 2013! Market Capitalisation! Shareholders! £33.8m! ! £24m! £26.8m! IP Group " " " " " "30%! £17m! Henderson Global
Slide 4: Results for the Period Ended 31st July 2013
Results for the Period Ended 31st July 2013
Slide 5: Summary Income Statement
Summary Income Statement 5! ! 2013! 2012! ! £000! £000! Avacta Animal Health revenue! 1,500! 1,488! Avacta Analytical revenue1! 1,200! 1,642! Total revenue! 2,700! 3,130! Total gross profit2! 1,513! 1,511! 56%! 48%! Administrative costs3! (3,251)! (3,061)! Operating loss before non-trading items! (1
Slide 6: Summary Cash Flow Statement and Balance Sheet
Summary Cash Flow Statement and Balance Sheet ! 2013! 2012! Cash flow statement! £000! £000! Operating cash flow before changes in working capital! (1,389)! (1,259)! Movement in working capital1! (535)! 509! Operating cash flow from operations! (1,924)! (750)! Interest and income tax received2! 547!
Slide 7: Business Update
7! Business Update
Slide 8: Analytical Division
Analytical Division Advanced protein analytics supporting bio-therapeutic developers.! Optim key facts :! • Bench top instrument.! • Single use consumable cartridge.! • Stability and formulation tool.! • 100x less sample than other methods.! • 100x faster than other methods.! • Detection of poor lea
Slide 9: Highlights in the Period: Optim Revenue
9! Highlights in the Period! Optim Revenue! • Product upgrade and US/Asia distributor training £1.0m! £1.3m! completed.! £0.8m! £0.1m! • Good H2 following slow H1; over 50 units now shipped.! • Rapid growth in sales prospects to over 250 with the majority in US, EU and Japan.! • Gross margin on unit
Slide 10: Animal Health Division
Animal Health Division Veterinary diagnostics business with good growth potential through launch of Sensipod in-clinic blood analyser and expansion of laboratory services and diagnostic products range.! Established Products and Services! – Laboratory testing for Revenue! environmental and food aller
Slide 11: Highlights in the Period and Strategy and Plans
11! Highlights in the Period! Strategy and Plans! – £1.5m revenue – remained steady – Grow non-allergy laboratory offering:! despite recessionary pressures on • Canine lymphoma! veterinary market.! • Plus a validated pipeline of further tests.! – Successful Sensipod field trial (and – Expand Sensipo
Slide 12: Sensipod
Sensipod Sensipod is an in-clinic testing system that has been developed to put gold standard laboratory testing into the hands of the veterinarian.! Sensipod key facts :! • Bench top instrument.! Market Drivers/Key Data! • Single use consumable cartridge.! 25,000 vet practices in EU and USA! • Carr
Slide 13: Sensipod Update
13! Sensipod Update! - Commercial launch post period end (September 2013).! - Plan for a measured roll-out during Q2/3 which will allow us to stress test manufacturing, supply and customer support processes.! - Accelerated commercial activities thereafter as test menu grows.! - Targeting a menu of s
Slide 14: Life Sciences Division
Life Sciences Division Affimers an engineered antibody alternative based on a small, robust protein scaffold.! Affimers key facts :! binding surface • Affinity comparable to antibodies.! • High quality and low batch to batch variability.! • Much easier and cheaper to manufacture.! • Stable and robus
Slide 15: Highlights in the Period and Strategy
15! Highlights in the Period! Strategy! • High throughput protein production facility Avacta Life Sciences is focused on two now producing ~1000 Affimers per week.! commercial applications of Affimers :! • Microarray printing protocols refined and • Reagents! technology transfer to manufacturing par
Slide 16: Affimer Microarrays
Affimer Microarrays 20k – 100k different Affimers per array Healthy sample applied Diseased sample applied an printed onto a standard glass slide! to an array, incubated, identical array, incubated, then washed off! then washed off! The differences in what sticks to the array are biomarkers of the d
Slide 17: The world's largest protein microarray
17! The world’s largest protein microarray! • Market drivers! The largest an%body – Huge pressure from regulators to develop companion diagnostics.! microarray, the Panorama Array – Biomarker discovery essential and currently challenging.! from Sigma Aldrich, • Product positioning! has 725 an%bodies
Slide 18: Summary and Outlook
Summary and Outlook Strong equity growth opportunity underpinned by revenue generating businesses! • In-clinic veterinary Sensipod analyser development completed and launched post-period end.! • Measured rollout of Sensipod planned during FY14 as test menu is expanded with a target of six tests in t
Slide 19: Important Notice
Important Notice 19! This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the “Company”) nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of i